Some overactive bladder drugs are linked to a modestly higher risk of dementia, and the risk appears to depend heavily on which drug you take. Large observational studies put the increase at roughly 20 percent for the older anticholinergic (antimuscarinic) class — drugs like oxybutynin, solifenacin and tolterodine — while alternatives that work differently show no such signal.
Overactive bladder (OAB) means sudden, hard-to-control urges to urinate, often with leakage or frequent night-time trips. Anticholinergic drugs treat it by blocking acetylcholine, a chemical messenger that makes the bladder muscle contract. The problem is that acetylcholine also carries signals involved in memory and attention, and some of these drugs reach the brain.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the numbers actually show
- Why the evidence is not settled
- Not all anticholinergics carry the same signal
- What about the alternative?
- What to do if you or a relative takes one of these drugs
- Where guidelines stand now
- Frequently Asked Questions
What the numbers actually show
A nested case-control study of UK primary care patients aged 55 and older found that any bladder anticholinergic prescription was associated with 1.18-fold higher odds of dementia, with oxybutynin, solifenacin and tolterodine the most strongly associated agents. A separate analysis of the French national medical-administrative database reached a similar figure, an adjusted odds ratio of 1.23, again concentrated in oxybutynin and solifenacin, with signs of a cumulative dose-response. A 1.18 or 1.23 odds ratio is a relative increase, not a personal verdict.
If your baseline ten-year risk of dementia were 10 percent, a 20 percent relative increase moves it to about 12 percent — real, but far from the step change the phrase "dementia risk" suggests to most readers. The French study also found that trospium showed no increased dementia risk. Trospium is a quaternary amine, a molecule shaped so that it crosses the blood-brain barrier poorly. That single finding is the most informative one in the whole literature: it suggests the risk tracks which drug reaches the brain, not bladder treatment in general.
Why the evidence is not settled
These are observational studies, and the biggest threat to them has a name: confounding by indication. Early dementia itself causes urinary symptoms, years before diagnosis. So some people prescribed a bladder drug at 72 may already be in the earliest stage of a disease that will be recorded as dementia at 76 — and the prescription looks like a cause when it was a consequence.
A population-based cohort that compared people starting anticholinergics against people starting beta-3 agonists found higher dementia incidence in the anticholinergic group (hazard ratio 1.23). But the comparison arm's median mirabegron prescription duration was only about 64 days, so it weighed short exposure to one drug against much longer exposure to the other. The UK's Medicines and Healthcare products Regulatory Agency published a formal review of this question in July 2026. Its Commission on Human Medicines concluded that although studies suggest an association, data complexity and study limitations leave "considerable uncertainty" about causality — four studies showed roughly 1.2-fold raised risk, while others showed no difference or even lower risk against active comparators.
Not all anticholinergics carry the same signal
The class is not uniform, and lumping the drugs together hides the useful detail. Oxybutynin appears in nearly every analysis that finds a signal. It is lipophilic, meaning it dissolves in fat and crosses into the brain more readily than trospium does.
A TriNetX analysis presented at the 2024 American Urological Association meeting sharpened this further. After adjusting for sex, comorbidity, medication type and total anticholinergic burden, only oxybutynin remained linked to higher dementia risk — about 12 percent — in women aged 65 and over compared with mirabegron. Roughly where the current evidence places each option:.
- **Oxybutynin** — the most consistently implicated; the one worth questioning first
- **Solifenacin and tolterodine** — implicated in the UK and French database studies
- **Trospium** — crosses into the brain poorly; no increased risk in the French analysis
- **Mirabegron (beta-3 agonist)** — a different mechanism; relaxes the bladder without blocking acetylcholine
What about the alternative?
Beta-3 agonists such as mirabegron relax the bladder muscle through a separate receptor, so they do not touch the acetylcholine system at all. The randomized evidence on their cognitive safety is encouraging but narrow. The phase 4 placebo-controlled PILLAR trial in patients aged 65 and over tracked cognition with the Montreal Cognitive Assessment and found that 12 weeks of mirabegron did not contribute to drug-related cognitive side effects. Twelve weeks is the limitation.
A trial that short can rule out an immediate cognitive hit; it cannot speak to what years of continuous use does. The honest summary is that mirabegron has no dementia signal in observational data and no short-term cognitive signal in a trial, which is the strongest safety profile on offer — not proof of long-term safety. Beta-3 agonists have their own trade-offs, notably blood pressure effects and cost, and they do not work for everyone. That is why the choice belongs with a prescriber who knows your other conditions.
What to do if you or a relative takes one of these drugs
Do not stop a bladder medication on your own. Untreated overactive bladder causes falls from rushing to the toilet at night, broken sleep, social withdrawal and skin breakdown — all of which carry their own risks in older adults, including for people already living with dementia.
The MHRA's practical advice is proportionate: older adults should limit the number of anticholinergic medicines they take and use the lowest effective dose for the shortest necessary duration, rather than abandoning bladder treatment. The cumulative point matters, because anticholinergic effects stack across drug classes — some antidepressants, antihistamines, antipsychotics and Parkinson's drugs add to the same total burden. Questions worth raising at the next appointment:.
- Which bladder drug am I on, and is it oxybutynin?
- What is my total anticholinergic burden across everything I take?
- Is a beta-3 agonist or trospium appropriate for me instead?
- Can the dose come down, or can we try a drug-free period?
- Have bladder training, timed voiding and pelvic floor exercises been tried properly?
Where guidelines stand now
The 2024 AUA/SUFU guideline on idiopathic overactive bladder still recommends offering either antimuscarinics or beta-3 agonists as a Strong Recommendation at Evidence Level A, while urging caution in frail patients and those with cognitive deficits. Accompanying AUA commentary goes further, saying prescribers should counsel patients that OAB anticholinergics may put them at risk of dementia.
That combination — keep both options on the table, but say the risk out loud — is the current standard of care. If nobody mentioned dementia risk when your prescription was written, that conversation is still owed to you.
Frequently Asked Questions
Does stopping the drug reverse the risk?
The studies described here measured dementia diagnoses in people who had been prescribed these drugs; they were not designed to test whether stopping changes outcomes. The possible cumulative dose-response seen in the French data is a reason to minimise total exposure going forward.
My relative already has dementia and takes oxybutynin. Does this still matter?
Anticholinergic drugs can worsen confusion and attention in people with existing cognitive impairment, which is why the AUA/SUFU guideline urges caution specifically in patients with cognitive deficits. Raise it with the prescriber, and ask about trospium or a beta-3 agonist.
Are over-the-counter bladder products safer?
Not automatically. Some non-prescription products for bladder and allergy symptoms are themselves anticholinergic, and they count toward the same cumulative burden the MHRA advises limiting. Bring every product, including supplements, to a medication review.





